Page last updated: 2024-10-24

verapamil and Stroke

verapamil has been researched along with Stroke in 30 studies

Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research Excerpts

ExcerptRelevanceReference
"In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2."9.14Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009)
"In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group."9.13Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008)
" In the present work, we investigated whether verapamil, an established TXNIP inhibitor, may provide protection against hyperglycemic stroke and tPA-induced blood-brain barrier (BBB) disruption."8.02Verapamil as an Adjunct Therapy to Reduce tPA Toxicity in Hyperglycemic Stroke: Implication of TXNIP/NLRP3 Inflammasome. ( Ahmed, HA; Ishrat, T; Ismael, S; Mirzahosseini, G; Nasoohi, S; Yoo, A, 2021)
"In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2."5.14Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009)
"In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group."5.13Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008)
" In the present work, we investigated whether verapamil, an established TXNIP inhibitor, may provide protection against hyperglycemic stroke and tPA-induced blood-brain barrier (BBB) disruption."4.02Verapamil as an Adjunct Therapy to Reduce tPA Toxicity in Hyperglycemic Stroke: Implication of TXNIP/NLRP3 Inflammasome. ( Ahmed, HA; Ishrat, T; Ismael, S; Mirzahosseini, G; Nasoohi, S; Yoo, A, 2021)
" James Women Take Heart (WTH; women without coronary disease at baseline), Women's Ischemia Syndrome Evaluation (women with signs/symptoms of ischemia at baseline), and the INternational VErapamil-Trandolapril STudy (INVEST; women with coronary artery disease and hypertension at baseline), totaling 15,108 adult women with no hypertension, non-RH (blood pressure [BP] ≥140/90 mmHg on ≤2 drugs or BP <140/90 mmHg on 1-3 drugs), or aRH (BP ≥140/90 mmHg on ≥3 drugs or anyone on ≥4 drugs) at baseline."3.83Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. ( Cooper-DeHoff, RM; Gong, Y; Gulati, M; Handberg, E; Huo, T; Merz, CN; Pepine, CJ; Smith, SM, 2016)
"This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease."3.77Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011)
" Administration of verapamil, an L-type calcium channel blocker which was effective for hypertension in SHRSP rats, prevented the decrease in plasma protein expression."3.74Proteomic identification of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone rats. ( Goto, H; Hayashi, K; Kiga, C; Saiki, I; Sakurai, H; Shimada, Y, 2008)
"Mycophenolic acid was detected in all cats."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"In part V of a series of papers on epidemiology and drug prevention of stroke and other thromboembolic complications of atrial fibrillation the authors analyze data of randomized trials exhibiting ability of long term use of beta-adrenoblockers, angiotensin converting enzyme inhibitors, angiotensin receptor antagonists and statins to prevent atrial fibrillation."1.32[Stroke and other thromboembolic complications of atrial fibrillation. Part v. The use of drugs without antithrombotic or antiarrhythmic properties.]. ( Batyraliev, TA; Kiktev, VG; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA, 2004)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (3.33)18.2507
2000's15 (50.00)29.6817
2010's12 (40.00)24.3611
2020's2 (6.67)2.80

Authors

AuthorsStudies
Anger, T1
Madge, DJ1
Mulla, M1
Riddall, D1
Redondo, M1
Zarruk, JG1
Ceballos, P1
Pérez, DI1
Pérez, C1
Perez-Castillo, A1
Moro, MA1
Brea, J1
Val, C1
Cadavid, MI1
Loza, MI1
Campillo, NE1
Martínez, A1
Gil, C1
Sava, RI1
Chen, YE1
Smith, SM2
Gong, Y3
Cooper-DeHoff, RM5
Keeley, EC1
Pepine, CJ9
Handberg, EM2
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B1
Wu, C1
Zhang, Z2
Yan, K1
Li, C2
Li, Y5
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J5
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J2
Yan, D1
Lou, H1
Yu, H1
Feng, C1
Wang, Z1
Wang, Y4
Hu, X1
Li, Z2
Shen, Y1
Hu, D1
Chen, H1
Wu, X1
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z1
Zhang, X2
Yang, X2
Zhang, J2
Wang, H1
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H2
Xing, Z1
Lu, G1
Chen, D1
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M1
Ye, M1
Wen, N1
Fu, M1
Fan, W2
Meng, Y1
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J2
Geng, Y1
Zhang, Y4
Wang, X2
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S1
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C2
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C1
Zhao, W1
Xia, X1
Jiang, Y1
Peng, J1
Jia, Z1
Li, F1
Chen, X2
Mo, J1
Zhang, S2
Li, X2
Huang, T1
Zhu, Q1
Wang, S1
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Zhu, D1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G1
Frew, R1
Guo, X1
Gong, Q1
Borowiec, J1
Han, S1
Zhang, M1
Willis, M1
Kreouzis, T1
Yu, K1
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q1
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S1
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J1
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S1
Deng, W1
Wu, D1
Zhang, Q1
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H1
Xu, C1
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Ismael, S1
Nasoohi, S1
Yoo, A1
Mirzahosseini, G1
Ahmed, HA1
Ishrat, T1
Fraser, JF2
Maniskas, M1
Trout, A1
Lukins, D1
Parker, L1
Stafford, WL1
Alhajeri, A1
Roberts, J1
Bix, GJ2
Washam, JB1
Hellkamp, AS1
Lokhnygina, Y1
Piccini, JP1
Berkowitz, SD1
Nessel, CC1
Becker, RC1
Breithardt, G1
Fox, KAA1
Halperin, JL1
Hankey, GJ1
Mahaffey, KW1
Singer, DE1
Patel, MR1
Huang, L1
Shang, E1
Li, B1
He, S1
Fu, Y1
Fang, W1
Carr, E1
Joudeh, L1
Maniskas, ME1
Roberts, JM1
Aron, I1
Khodneva, Y1
Shalev, A1
Frank, SJ1
Carson, AP1
Safford, MM1
Lena, J1
Eskandari, R1
Infinger, L1
Fargen, KM1
Spiotta, A1
Turk, A1
Turner, RD1
Chaudry, I1
Huo, T1
Handberg, E2
Gulati, M1
Merz, CN1
Bangalore, S2
Messerli, FH5
Cohen, JD2
Bacher, PH1
Sleight, P2
Mancia, G4
Kowey, P1
Zhou, Q2
Champion, A4
Kiga, C1
Sakurai, H1
Goto, H1
Hayashi, K1
Shimada, Y1
Saiki, I1
Franklin, SS1
Fletcher, JJ1
Kramer, AH1
Bleck, TP1
Solenski, NJ1
Knierim, E1
Leisle, L1
Wagner, C1
Weschke, B1
Lucke, B1
Bohner, G1
Dreier, JP1
Schuelke, M1
Bavry, AA1
Khaliq, A1
Gilbert, GJ1
White, WB1
LaRocca, GM1
Liebson, PR1
Williams, B1
Preobrazhenskiĭ, DV1
Sidorenko, BA1
Kiktev, VG1
Batyraliev, TA1
Pershukov, IV1
Kowey, PR1
Kupfer, S3
Kolloch, RE1
Benetos, A3
Coca, A2
Gaxiola, E1
Conti, CR2
Hewkin, AC3
Tavazzi, L1
Kolloch, R1
Cooper-Dehoff, R1
Bakris, GL1
Erdine, S1
Smeda, JS1
VanVliet, BN1
King, SR1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
INternational VErapamil SR Trandolapril STudy[NCT00133692]Phase 422,000 participants Interventional1997-09-30Completed
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151]Phase 2138 participants (Anticipated)Interventional2021-02-08Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for verapamil and Stroke

ArticleYear
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
    Journal of medicinal chemistry, 2001, Jan-18, Volume: 44, Issue:2

    Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Mo

2001
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
Chronopharmacology of cardiovascular therapy.
    Blood pressure monitoring, 2002, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Blood Pressu

2002
Protection against stroke and dementia: an update on the latest clinical trial evidence.
    Current hypertension reports, 2004, Volume: 6, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl

2004

Trials

6 trials available for verapamil and Stroke

ArticleYear
Intra-arterial verapamil post-thrombectomy is feasible, safe, and neuroprotective in stroke.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2017, Volume: 37, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Brain Ischemia; Cell Death; Cells,

2017
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
    The American journal of cardiology, 2017, Aug-15, Volume: 120, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem

2017
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    American heart journal, 2008, Volume: 156, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Atenol

2008
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
    European heart journal, 2009, Volume: 30, Issue:11

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Coronary Disease;

2009
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
    Annals of internal medicine, 2006, Jun-20, Volume: 144, Issue:12

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cause of Death; Coronary Artery Disease; Di

2006
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
    The American journal of cardiology, 2006, Oct-01, Volume: 98, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann

2006
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
    The American journal of cardiology, 2006, Oct-01, Volume: 98, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann

2006
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
    The American journal of cardiology, 2006, Oct-01, Volume: 98, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann

2006
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
    The American journal of cardiology, 2006, Oct-01, Volume: 98, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann

2006

Other Studies

20 other studies available for verapamil and Stroke

ArticleYear
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
    European journal of medicinal chemistry, 2012, Volume: 47, Issue:1

    Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease

2012
Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST).
    Journal of women's health (2002), 2020, Volume: 29, Issue:2

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Cha

2020
Verapamil as an Adjunct Therapy to Reduce tPA Toxicity in Hyperglycemic Stroke: Implication of TXNIP/NLRP3 Inflammasome.
    Molecular neurobiology, 2021, Volume: 58, Issue:8

    Topics: Animals; Carrier Proteins; Drug Therapy, Combination; Fibrinolytic Agents; Hyperglycemia; Male; Mice

2021
S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Nov-15, Volume: 109

    Topics: Animals; Atenolol; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cla

2017
A Young Woman With A History of Stroke and Recurrent Migraine Headaches.
    Mayo Clinic proceedings, 2019, Volume: 94, Issue:6

    Topics: Adult; Anti-Arrhythmia Agents; Biopsy; CADASIL; Female; Humans; Magnetic Resonance Imaging; Migraine

2019
Stroke neuroprotection revisited: Intra-arterial verapamil is profoundly neuroprotective in experimental acute ischemic stroke.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2016, Volume: 36, Issue:4

    Topics: Acute Disease; Animals; Apoptosis; Behavior, Animal; Brain Ischemia; Calcium Channel Blockers; Cell

2016
Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study.
    Diabetes research and clinical practice, 2016, Volume: 115

    Topics: Adult; Aged; Biomarkers; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus; Dose-Response R

2016
Basilar artery occlusion in a child treated successfully with mechanical thrombectomy using ADAPT.
    BMJ case reports, 2016, Apr-11, Volume: 2016

    Topics: Arterial Occlusive Diseases; Basilar Artery; Cerebral Angiography; Child; Combined Modality Therapy;

2016
Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease.
    Journal of women's health (2002), 2016, Volume: 25, Issue:10

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Artery Disease; Drug Resistance; Fema

2016
Proteomic identification of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone rats.
    Life sciences, 2008, Oct-24, Volume: 83, Issue:17-18

    Topics: Animals; Biomarkers; Blood Proteins; Haptoglobins; Hypertension; Male; Proteomics; Rats; Rats, Inbre

2008
Overlapping features of eclampsia and postpartum angiopathy.
    Neurocritical care, 2009, Volume: 11, Issue:2

    Topics: Adult; Cerebrovascular Disorders; Eclampsia; Female; Headache; Humans; Methylprednisolone; Nicardipi

2009
Recurrent stroke due to a novel voltage sensor mutation in Cav2.1 responds to verapamil.
    Stroke, 2011, Volume: 42, Issue:2

    Topics: Calcium Channels; Calcium Channels, N-Type; Child; Female; Humans; Mutation; Secondary Prevention; S

2011
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
    The American journal of medicine, 2011, Volume: 124, Issue:7

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec

2011
Cerebral vasoconstriction and stroke after use of serotonergic drugs.
    Neurology, 2002, Aug-27, Volume: 59, Issue:4

    Topics: Cerebrovascular Circulation; Humans; Migraine Disorders; Serotonin Agents; Stroke; Vasoconstriction;

2002
VISP and INVEST.
    Preventive cardiology, 2004,Spring, Volume: 7, Issue:2

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers;

2004
[Stroke and other thromboembolic complications of atrial fibrillation. Part v. The use of drugs without antithrombotic or antiarrhythmic properties.].
    Kardiologiia, 2004, Volume: 44, Issue:12

    Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Stroke; Verapamil

2004
Adult hypertension: reducing cardiovascular morbidity and mortality.
    Prescrire international, 2005, Volume: 14, Issue:75

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking

2005
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
    Journal of the American College of Cardiology, 2006, Feb-07, Volume: 47, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium

2006
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
    Stroke, 2008, Volume: 39, Issue:2

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; D

2008
Stroke-prone spontaneously hypertensive rats lose their ability to auto-regulate cerebral blood flow prior to stroke.
    Journal of hypertension, 1999, Volume: 17, Issue:12 Pt 1

    Topics: Animals; Blood Pressure; Cerebrovascular Circulation; Diet; Homeostasis; Hypertension; In Vitro Tech

1999